Organization
Advicenne Pharma
4 clinical trials
2 abstracts
Clinical trial
A Phase 3B Open-Label Extension Of Study B23CS (ARENA 2) Evaluating The Continued Safety And Efficacy Of ADV7103 In Subjects With Primary Distal Renal Tubular AcidosisStatus: Withdrawn, Estimated PCD: 2025-01-01
Clinical trial
A Phase 3 Multicenter, Randomized, Double-Blinded, Placebo-Controlled Withdrawal Study Evaluating ADV7103 In Pediatric and Adult Subjects With Distal Renal Tubular Acidosis (dRTA)Status: Terminated, Estimated PCD: 2023-12-20
Clinical trial
Open Label, Multicentre Study, Evaluating the Safety, Tolerability, Efficacy, Compliance and Acceptability of Alkalising Treatments at Long-term in Patients With CystinuriaStatus: Withdrawn, Estimated PCD: 2025-06-01
Clinical trial
A Multicentre, Randomized, Controlled Versus Placebo, Double-blinded, 4 Parallel Arms, Dose-ranging Main Study, to Evaluate the Efficacy, Safety and Tolerability and Acceptability of Repeated Doses of ADV7103, After 7 Days of Treatment, in Patients With Cystinuria, and an Efficacy and Safety Exploratory Study in the Youngest Children.Status: Not yet recruiting, Estimated PCD: 2025-05-01
Abstract
Symptoms reported by patients using an ePRO compared with those reported to nurses via telephone triage.Org: Advicenne Pharma, Canopy Care, Northwest Medical Specialties, Highlands Oncology Group, Cancer Specialists of North Florida,
Abstract
Electronic patient-reported outcomes in a cohort of patients with lung cancer treated in the community with shorter versus longer course PD1/PDL1 therapy.Org: Advicenne Pharma, Canopy Growth, Highlands Oncology Group, Northwest Medical Specialties, CSNF,